BiotechTube

efatutazone

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Liposarcoma

Conditions

Liposarcoma

Trial Timeline

Feb 11, 2015 → May 1, 2023

NCT ID
NCT02249949

About efatutazone

efatutazone is a phase 2 stage product being developed by Daiichi Sankyo for Liposarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02249949. Target conditions include Liposarcoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02249949Phase 2Completed

Competing Products

12 competing products in Liposarcoma

See all competitors
ProductCompanyStageHype Score
Abemaciclib + PlaceboEli LillyPhase 3
77
Eribulin MesylateEisaiPhase 1
33
Trabectedin + DexamethasoneJohnson & JohnsonPhase 2
52
Yondelis + Yondelis + Dexamethasone + DexamethasoneJohnson & JohnsonPhase 2
52
HDM201 + LEE011NovartisPhase 1
33
pazopanibNovartisPhase 2
52
PF-07220060 + MidazolamPfizerPhase 2
51
Sunitinib Malate (SU011248)PfizerPhase 2
51
CabazitaxelSanofiPhase 2
51
INCMGA00012 + PalbociclibIncytePhase 2
49
Selinexor + PlaceboKaryopharm TherapeuticsPhase 2/3
57
Selinexor + IxazomibKaryopharm TherapeuticsPhase 1
25

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85